Akero Therapeutics, Inc. financial data

Symbol
AKRO on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 07 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1578% % -35%
Debt-to-equity 7% % -17%
Return On Equity -31% % 5.7%
Return On Assets -29% % 4.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 82,316,179 shares 18%
Common Stock, Shares, Outstanding 80,149,218 shares 15%
Entity Public Float $1,569,636,109 USD -38%
Common Stock, Value, Issued $8,000 USD 14%
Weighted Average Number of Shares Outstanding, Basic 82,008,267 shares 18%
Weighted Average Number of Shares Outstanding, Diluted 82,008,267 shares 18%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $286,997,000 USD 24%
General and Administrative Expense $43,019,000 USD 14%
Operating Income (Loss) $330,016,000 USD -23%
Net Income (Loss) Attributable to Parent $292,820,000 USD -23%
Earnings Per Share, Basic -3 USD/shares 1.3%
Earnings Per Share, Diluted -3 USD/shares 1.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $176,032,000 USD -44%
Marketable Securities, Current $561,794,000 USD 40%
Cash, Cash Equivalents, and Short-term Investments $988,316,000 USD 26%
Assets, Current $754,535,000 USD 1%
Property, Plant and Equipment, Net $15,000 USD -25%
Operating Lease, Right-of-Use Asset $552,000 USD -33%
Assets $1,005,577,000 USD 23%
Accounts Payable, Current $20,399,000 USD -19%
Employee-related Liabilities, Current $4,976,000 USD 14%
Liabilities, Current $47,651,000 USD 10%
Operating Lease, Liability, Noncurrent $289,000 USD -52%
Liabilities $47,940,000 USD -39%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,826,000 USD -13%
Retained Earnings (Accumulated Deficit) $1,048,952,000 USD -39%
Stockholders' Equity Attributable to Parent $957,637,000 USD 30%
Liabilities and Equity $1,005,577,000 USD 23%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $67,664,000 USD -93%
Net Cash Provided by (Used in) Financing Activities $395,531,000 USD 7.8%
Net Cash Provided by (Used in) Investing Activities $482,183,000 USD -934%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 80,149,218 shares 15%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $176,032,000 USD -44%
Interest Paid, Excluding Capitalized Interest, Operating Activities $980,000 USD 28%
Deferred Tax Assets, Valuation Allowance $241,751,000 USD 37%
Deferred Tax Assets, Gross $248,945,000 USD 38%
Operating Lease, Liability $605,000 USD -32%
Depreciation $1,000 USD -91%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $293,097,000 USD -25%
Lessee, Operating Lease, Liability, to be Paid $646,000 USD -34%
Lessee, Operating Lease, Liability, to be Paid, Year Two $208,000 USD -41%
Lessee, Operating Lease, Liability, to be Paid, Year One $351,000 USD 2.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $41,000 USD -57%
Lessee, Operating Lease, Liability, to be Paid, Year Three $208,000 USD -41%
Deferred Tax Assets, Operating Loss Carryforwards $115,713,000 USD 31%
Unrecognized Tax Benefits $5,891,000 USD 74%
Operating Lease, Payments $333,000 USD 2.8%
Additional Paid in Capital $1,497,264,000 USD 44%
Deferred Tax Assets, Net of Valuation Allowance $7,194,000 USD 168%
Share-based Payment Arrangement, Expense $34,276,000 USD 20%
Interest Expense $4,618,000 USD 5.8%